Business StandardCenter·
Lupin to bet big on biosimilar sales in mid term, ramp capacity expansion
The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes
Read at Business Standard →




